HPV Vaccination
Beginning January 2023, continue two doses for 9- and 10-year-old girls and include 9- and 10-year-old boys.
In addition, conduct outreach campaign with health personnel for the application of the vaccine.
Resume the participation of MINED.
Pneumococcal vaccination in the elderly
The recommendation is to start with conjugate vaccines (PCV13) and then administer PPSV23 in those over 65 years of age.
If it is done the other way around, first PPSV23, the placement of PCV13 should be generated 1 year later, not shortening the time. Immunologically, due to the vaccinal response of PPSV23, this interval of at least 1 year is recommended.
If there are immunocompromising conditions, cochlear implants, or CSF fistulas, it can be placed as early as 8 weeks.
In persons with chronic conditions under 65 years of age, the recommendation is similar.
SARS-COV-2 vaccination in immunosuppressed patients
Defer the use of live vaccines until adequate immune function is restored.
Use of inactivated vaccines should be repeated because the efficacy of a single dose is suboptimal efficacy.
Complete vaccination schedules at least 2 weeks prior to initiation of immunosuppressive therapies.
Vaccination against COVID-19 and immunocompromised patients:
HIV:
Should receive a complete series, regardless of CD4 count and viral load.
Solid organ transplantation
Limited vaccine response
Vaccinate 2 weeks prior to surgery
If generated post-transplant, should be at least 3 months post-transplant as long as no acute cellular rejection is present
If on anti-CD20 therapy, should be vaccinated 6 months later
All health personnel and caregivers should have complete vaccination schedules.
Vaccination in children from 5 years old to 11 years 11 months 29 days old
Vaccine to be used: COVID 19 mRNA vaccine from Pfizer BioNtech COMIRNATY (Tozinameran) orange cap.
Dosage and route of administration: 0.2ml per dose. Three doses. The second dose should be administered 21 days after the first dose, if there is a delay, administer as soon as possible. Third dose: 5 months after the first dose, if there is a delay, administer as soon as possible.
Children with moderate to severe immunosuppression: 4 doses
2nd dose: 21 days after the 1st dose
3rd dose: 4 weeks or 28 days after 2nd dose
4th dose: 3 months after the 3rd dose
Route of administration: Intramuscular in the deltoid muscle.
Another vaccine that can be used in children aged 5 to 11 years is the COVID 19 mRNA vaccine from the laboratory producer Moderna
Dosage and route of administration: 0.25 ml per dose intramuscularly in the deltoid muscle.
Syringe to be used: 23G x 1 syringe of 1ml.
Two doses: The second dose should be administered at least 28 days after the first dose. Ideally, it should start and end with a vaccine from the same producing laboratory, but this will depend on the availability of the product.
Keywords